Close Menu

NEW YORK – Biotech company Acepodia said Thursday that the US Food and Drug Administration accepted the investigational new drug application for its new antibody-cell conjugate based immunotherapy, ACE1702, for patients with HER2-expressing solid tumors. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.